Semaglutide, a drug commonly taken for weight loss, showed marked benefits for most patients in a trial for metabolic dysfunction-associated steatohepatitis (MASH)

Prior to starting the trial, the participants also had moderate to high levels of scar tissue in the liver, known as stage 2 or 3 fibrosis.

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by the common condition.